Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody ... advanced EGFR-mutated non-small cell lung cancer (NSCLC).

so it's like a double regulation there with this miR-205 regulation of both MED1 and HER3," Zhang said. "Subsequent studies ...

A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate ... pre-treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), including an objective response rate ...

“With the other arm, one can zoom in and block a molecule such as HER3 that is expressed at a ... more effective at inhibiting the growth of cell lines resistant to HER2-targeted therapies ...